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tions to improve limited HL. METHODS: Systematic review
with electronic database searches (MEDLINE, EMBASE,
PsycINFO, CINHAL and COCHRANE-Library; from 1980
through January 2008), screening of selected books and reference
lists, and expert contacts. We included observational and inter-
ventional studies that reported HL of participants as one
outcome measure. We included populations at high risk for low
HL as well as patients with 1) diabetes mellitus, or 2) hyperlipi-
demia. Studies were screened for eligibility, unclear cases were
discussed in a consensus meeting. We performed data extraction
and quality assessment; results were checked by a second
reviewer. RESULTS: We retrieved 2340 papers and included 10
studies for the ﬁnal analysis. On the health care system level, the
additional spending due to low HL corresponds to 3% to 5% of
the total health care costs (3 studies with data of more than
50,000 persons from U.S. and Swiss settings). The prevalence of
limited HL is considerable (range: 34% to 59%; 4 studies;
110,000 nationally representative persons). Three U.S. studies
(data of 3600 persons) report the additional costs of limited HL
on the patient level (additional expenditures per year per person
with limited HL compared to a reference group with adequate
HL; range: US $143 to 7798). One systematic review reported
cost-effectiveness data of patient self management programs for
diabetes and showed inconclusive results. CONCLUSIONS: The
costs of limited HL for the health care system may be substantial,
but few studies were retrieved, and the results are heterogeneous.
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OBJECTIVES: To analyze the costs and discharge status for
patients with prolonged mechanical ventilation undergoing tra-
cheostomy (DRG code 483) in Spain and to examine the impact of
age in terms of hospital outcome. METHODS: From the
2004 National Hospital Discharge Database records for all
patients aged >16 years undergoing mechanical ventilation were
retrieved. Demographic characteristics, clinical outcomes and
hospital-resources utilization were examined. An exploratory
logistic regression analysis and a multiple linear regression analy-
sis were performed to identify factors associated with in-hospital
mortality and LOS respectively. To depict the amount of resources
spent to procure a given level of desired outcome (hospital sur-
vival) we also determined the cost per survivor based in the
average National Health Service Charges for DRG 483
(€49,365.37).RESULTS: From a total of 33,416 cases undergoing
mechanical ventilation during 2004, 4,277 cases (13%) with a
ﬁnal DRG code of 483 were selected and eligible for analysis.
Median age was 65 yr (p25:50; p75:73); 67%were men and 54%
surgical patients. According to Charlson index, 56% of cases had
no associated comorbidity. Overall in-hospital mortality was
41%. Total costs of hospitalizations exceeded € 211 million. An
inverse relationship between survival rate and age was consis-
tently observed after adjusting by other clinical variables, and this
resulted in an age-related increased cost per survivor (€58,588 in
patients aged <45 yrs; €75,1531 in those aged 45–64 yrs; 99,720
in 65–74 yrs and €12,5903 in those older than 74 yrs).CONCLU-
SIONS: Patients who require tracheostomy for prolonged
mechanical ventilation have high resource utilization and rela-
tively poor outcomes. Age has a signiﬁcant impact on outcomes in
patients under DRG 483 both from clinical and economic per-
spectives. These analyses will help inform health care decision-
making and resource planning in the face of an ageing population.
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OBJECTIVES: In the Hungarian DRG system it can frequently
occur that real costs exceed the amount of reimbursements. Our
goal was to compare the difference between the real clinical cost
and the normative DRG reimbursement in a single patient case.
METHODS: Data derive from the ﬁnancial database of the
National Health Insurance Fund Administration (NHIFA) and
the clinical database of the University of Pecs. We made an outlay
of the patient’s variable costs for drugs, infusions, nutritive prod-
ucts, transfusions, laboratory diagnostics and imagining proce-
dures used. The results we obtained were compared to standards
calculated by the NHIFA for the surgical treatment of oesoph-
ageal cancer. The case was grouped to DRG code number 9540
which had 13.2 weight-number. RESULTS: The weight-number
of medication components in this DRG category was 1.68
(12.7% of the total 13.2 weight-number). The real medication
cost was HUF 3,960,000 which represented 39.6 weight-number.
This exceeded the DRG medication reimbursement 23.6 times
and was 3 times more than the total reimbursement. In this way
just the medication cost was 300% of the total DRG ﬁnancing.
The excess cost was generated by increased drug usage due to
the patient’s severe septic complications. The main elements of
medications were a four-day activated protenine-C treatment
representing 53.5% of total drug expenditure, IgM enriched
polyclonal antibody therapy (28.4%) and 5 different antibiotics
(7.24%). The treatment of severe sepsis made up 89.1% of total
medication cost. As an excess, 27.6 weight-number was reim-
bursed topping the 13.2 weight-number for the original DRG.
CONCLUSIONS: There was a signiﬁcant gap between real hos-
pital costs and health insurance reimbursement. On the basis of
this analysis, the NHIFA found our demand for extra ﬁnance
justiﬁed and reimbursed our institution with the extra cost
applied for. Our case signiﬁcantly contributed to regulation
changes dealing with extra ﬁnancing for outlayer patient’s costs
in the DRG system.
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OBJECTIVES: German hospital reimbursement changed signiﬁ-
cantly as a result of the introduction of Diagnosis Related
Groups (DRG) in the year 2004. Based on this development no
current data on the direct costs of adverse drug reactions (ADR)
leading to hospital admissions in departments of internal
medicine is available. The objective of our project is to quantify
the ADR-related economic burden of the respective ADRs in
Germany. METHODS: A total of 1242 patient records of ADRs
leading to internal medicine hospitalization were surveyed in 4
regional pharmacovigilance centres in Germany within the years
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